Wobble Genomics to Present Full-Length mRNA Sequencing Data at AACR 2026

Wobble Genomics will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting its method for sequencing full-length mRNA from blood samples to aid in antibody-drug conjugate (ADC) therapy selection for breast cancer patients, announced in a press release.

The presentation, titled Sequencing Full-Length mRNA in Whole Blood of Breast Cancer Patients for ADC Therapy Selection, will take place on April 20, 2026, from 2:00–5:00 PM in Poster Section 45, Board #4, Poster #3843. The research is part of the “Liquid Biopsies: Circulating Nucleic Acids 3” session.

According to the company, the approach enables comprehensive mRNA profiling directly from blood, potentially reducing the need for invasive tissue biopsies. By capturing full-length transcripts, the data could help identify optimal treatment options and improve precision in therapy matching for patients undergoing complex treatments such as ADCs.

Wobble Genomics stated that it will engage with researchers, clinicians, and partners during the conference to discuss the application of its RNA sequencing technology in translational and therapeutic development.